TipRanks
Advertisement
Advertisement
Kymera Therapeutics placed on ‘Positive Catalyst Watch’ at JPMorgan
PremiumThe FlyKymera Therapeutics placed on ‘Positive Catalyst Watch’ at JPMorgan
22d ago
Kymera Therapeutics resumed with Early-Stage Biotech at Goldman Sachs
Premium
The Fly
Kymera Therapeutics resumed with Early-Stage Biotech at Goldman Sachs
26d ago
Kymera Therapeutics price target raised to $152 from $132 at Stifel
Premium
The Fly
Kymera Therapeutics price target raised to $152 from $132 at Stifel
28d ago
Kymera Therapeutics price target raised to $170 from $135 at Guggenheim
PremiumThe FlyKymera Therapeutics price target raised to $170 from $135 at Guggenheim
2M ago
Kymera Therapeutics Speeds Pipeline Amid Rising Spend
Premium
Company Announcements
Kymera Therapeutics Speeds Pipeline Amid Rising Spend
2M ago
Kymera Therapeutics price target raised to $135 from $119 at Morgan Stanley
Premium
The Fly
Kymera Therapeutics price target raised to $135 from $119 at Morgan Stanley
2M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―